Quotient Sciences and Biorasi have announced a strategic partnership aimed at streamlining early phase clinical trials from Investigational New Drug (IND) applications to patient proof-of-concept (POC) milestones. The collaboration will leverage Quotient Sciences’ expertise in early clinical development and clinical pharmacology, along with their facilities in Miami and Nottingham, to support Phase I and IIa studies. This will be supplemented by Biorasi’s global patient recruitment network, which spans multiple therapeutic areas including dermatology, neurology, nephrology, cell therapy, and other specialty fields.
The partnership is structured to offer a single provider model, enabling biotech and pharmaceutical sponsors to progress from first-in-human trials to POC through unified protocols and regulatory submissions, aiming to reduce outsourcing complexity and accelerate development timelines. The approach also addresses industry demand for integrated patient assessments and biomarker analysis in early clinical studies by expanding patient access through academic and commercial partnerships.
By deploying hybrid and multi-part protocols that include both healthy volunteer and patient cohorts, the collaboration seeks to improve efficiency and scientific rigor in generating early clinical data. Adjacent services such as pharmacy compounding, drug product manufacturing, data science, and regulatory support are also included in the expanded offerings. The initiative reflects ongoing trends in clinical trial innovation and aims to help sponsors advance new therapies more quickly through critical early development stages.